-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Do Institutions Own Jiangsu gdk Biotechnology Co., Ltd. (SHSE:688670) Shares?
Do Institutions Own Jiangsu gdk Biotechnology Co., Ltd. (SHSE:688670) Shares?
Every investor in Jiangsu gdk Biotechnology Co., Ltd. (SHSE:688670) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Warren Buffett said that he likes "a business with enduring competitive advantages that is run by able and owner-oriented people." So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.
Jiangsu gdk Biotechnology is a smaller company with a market capitalization of CN¥4.1b, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions own shares in the company. Let's take a closer look to see what the different types of shareholders can tell us about Jiangsu gdk Biotechnology.
See our latest analysis for Jiangsu gdk Biotechnology
SHSE:688670 Ownership Breakdown July 13th 2022What Does The Institutional Ownership Tell Us About Jiangsu gdk Biotechnology?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
We can see that Jiangsu gdk Biotechnology does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Jiangsu gdk Biotechnology's earnings history below. Of course, the future is what really matters.
SHSE:688670 Earnings and Revenue Growth July 13th 2022Hedge funds don't have many shares in Jiangsu gdk Biotechnology. Liangbin Zhang is currently the largest shareholder, with 31% of shares outstanding. In comparison, the second and third largest shareholders hold about 31% and 3.8% of the stock. Interestingly, the bottom two of the top three shareholders also hold the title of Senior Key Executive and Member of the Board of Directors, respectively, suggesting that these insiders have a personal stake in the company.
After doing some more digging, we found that the top 2 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held.
Insider Ownership Of Jiangsu gdk Biotechnology
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
It seems that insiders own more than half the Jiangsu gdk Biotechnology Co., Ltd. stock. This gives them a lot of power. So they have a CN¥2.8b stake in this CN¥4.1b business. Most would be pleased to see the board is investing alongside them. You may wish todiscover (for free) if they have been buying or selling.
General Public Ownership
The general public-- including retail investors -- own 21% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
Private Company Ownership
Our data indicates that Private Companies hold 3.0%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.
Next Steps:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. For instance, we've identified 3 warning signs for Jiangsu gdk Biotechnology (1 is significant) that you should be aware of.
If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
江蘇廣德科生物科技股份有限公司(上證號:688670)的每一位投資者都應該意識到最強大的股東羣體。一般來説,隨着公司的成長,機構會增加他們的持股。相反,隨着時間的推移,內部人士往往會減少他們的持股。沃倫·巴菲特説,他喜歡“一家由有能力、以所有者為導向的人經營的、具有持久競爭優勢的企業”。因此,看到一些內部人持股是件好事,因為這可能表明管理層是以所有者為導向的。
江蘇廣發生物科技是一家規模較小的公司,市值為41億元人民幣,因此它可能仍在許多機構投資者的雷達下飛行。我們對公司所有權的分析如下所示,機構擁有公司的股份。讓我們仔細看看不同類型的股東能告訴我們關於江蘇廣德科生物科技的什麼。
查看我們對江蘇廣德科生物科技的最新分析
上海證交所:688670所有權明細2022年7月13日關於江蘇廣發生物科技,機構持股告訴了我們什麼?
機構通常在向自己的投資者報告時,以基準來衡量自己,因此一旦一隻股票被納入主要指數,它們往往會對這隻股票變得更加熱情。我們預計,大多數公司都會有一些機構登記在冊,特別是在它們正在增長的情況下。
我們可以看到,江蘇廣電生物科技確實有機構投資者,他們持有公司很大一部分股票。這表明在專業投資者中有一定的可信度。但我們不能僅僅依靠這一事實,因為機構有時會做出糟糕的投資,就像每個人一樣。如果多家機構同時改變對一隻股票的看法,你可能會看到股價迅速下跌。因此,下面是江蘇廣電生物科技的盈利歷史,值得一看。當然,未來才是真正重要的。
上海證交所:2022年7月13日收益和收入增長688670對衝基金在江蘇廣發生物科技的股份並不多。張良斌目前是第一大股東,持有31%的流通股。相比之下,第二大股東和第三大股東分別持有約31%和3.8%的股份。有趣的是,前三名股東中排名墊底的兩名股東還分別持有高級關鍵高管和董事會成員的頭銜,這表明這些內部人士擁有公司的個人股權。
在進一步挖掘後,我們發現,前兩名股東共同控制着公司一半以上的股份,這意味着他們擁有相當大的權力來影響公司的決策。
雖然研究一家公司的機構所有權數據是有意義的,但研究分析師的情緒以瞭解風向也是有意義的。目前,我們沒有注意到分析師對該股的報道,因此該公司不太可能被廣泛持有。
江蘇GDK生物技術公司的內部人所有權
儘管對內部人的準確定義可能是主觀的,但幾乎每個人都認為董事會成員是內部人。公司管理層管理企業,但首席執行官將向董事會負責,即使他或她是董事會成員。
我通常認為內部人持股是一件好事。然而,在某些情況下,這會讓其他股東更難讓董事會對決策負責。
看來,內部人士持有江蘇廣電生物科技股份有限公司一半以上的股份。這給了他們很大的權力。因此,他們在這筆41億元的業務中擁有28億元的股份。大多數人會高興地看到董事會與他們一起投資。您可能希望發現(免費)如果他們一直在買入或賣出。
一般公有制
包括散户投資者在內的普通公眾持有該公司21%的股份,因此不能輕易忽視。雖然這羣人不一定能發號施令,但它肯定能對公司的運營方式產生真正的影響。
私營公司所有權
我們的數據顯示,私營公司持有該公司3.0%的股份。或許有必要對此進行更深入的研究。如果關聯方,如內部人士,對這些私營公司中的一家有利害關係,則應在年報中披露。私營公司也可能對該公司擁有戰略利益。
接下來的步驟:
雖然考慮擁有一家公司的不同集團是很值得的,但還有其他更重要的因素。例如,我們已經確定江蘇廣德科生物科技的三個警示(1是重要的),您應該知道。
如果你更願意看看另一家公司--一家財務狀況可能更好的公司--那麼不要錯過這一點免費令人感興趣的公司名單,有強勁的財務數據支持。
注:本文中的數字是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧